Veru exploring strategic alternatives for its legacy female health business

Miami, march 08, 2021 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has engaged morgan stanley & co. llc as a financial advisor to assist the company and its management in pursuing strategic alternatives regarding its legacy fc2 female condom® / fc2 internal condom business (fhc business).
VERU Ratings Summary
VERU Quant Ranking